MR1 and prostate cancer: Finally, we report that 5-A-RU elicits MR-1-dependent lysis of a prostate cancer cell line by human PBMCs in vitro, and that this effect is enhanced by pembrolizumab, in association with increased MAIT-cell expression of the cytotoxicity-associated molecules CD107a and IFN-γ.